**KEY FACTS**
The Alvin J. Siteman Cancer Center is a National Cancer Institute (NCI) designated comprehensive cancer center, the only one in Missouri and within a 240 mile radius. Siteman was awarded comprehensive status, the NCI’s highest level of distinction, because of its strong basic and clinical research, as well as its screening and prevention programs.

**Faculty:** More than 350 Washington University physicians and researchers

**Established:** In 1999 with a gift from Ruth and Alvin J. Siteman

**Director:** Timothy J. Eberlein, MD
Bixby Professor and Olin Distinguished Professor
Chair, Dept. of Surgery and Surgeon-in-Chief at Barnes-Jewish Hospital

**Patients:** #3 in the U.S. based on number of patients cared for in first year of treatment. In 2010, more than 8,000 newly diagnosed patients with continuing care to more than 40,000 individuals.

**Ranking:** Washington University, School of Medicine is ranked #4 in the nation, according to the 2010 U.S. News & World Report.

**RESEARCH**

**SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE):** The SPORE was launched by the NCI to support innovative research that would speed discoveries in the lab into actual patient care. In 2009, Siteman Cancer Center (SCC) and Washington University (WU) were awarded their first ever SPORE in endometrial cancer and are collaborating on research that will lead to the submission of additional SPOREs.

**University Genome Center:** The study of cancer genomics has the capacity to transform the future of cancer research. SCC is uniquely positioned to lead this exciting area with its strong relationship with the WU Genome Center. Examining a patient’s genetic material holds great promise for unraveling the mysteries of cancer. Researchers at SCC made history by being the first to decode the DNA of a human disease by sequencing the full genome of a patient with Acute Myeloid Leukemia.

**Siteman Center of Cancer Nanotechnology Excellence:** Nanotechnology is the next step in personalized medicine. Nanoparticles are used to locate and kill cancer cells by delivering toxic drugs directly to the tumor, without injuring normal tissue.

**Translational Research and Clinical Studies:** Translational Research represents the process of taking an innovative scientific hypothesis, performing “basic research” to test the idea—and once promising—conducting a clinical trial on actual patients. All new treatment protocols begin as clinical studies. At any given time, Siteman Cancer Center is conducting more than 300 clinical studies.
**Patient Care**

**Oncologic Imaging:** Among its long history with imaging research, the first CT and PET scan research was conducted at WU. Today, researchers are pioneering a new diagnostic-photoacoustic imaging, which provides extraordinary contrast and high spatial resolution. Many believe that photoacoustic imaging may become as great a contribution to modern imaging as the discovery of the x-ray.

**Kling Center for Proton Therapy:** Proton therapy is revolutionizing radiation treatment. In contrast to x-ray-based radiation, proton deposits its dose at the site of the tumor and not beyond, resulting in less damage to healthy tissue.

**Joanne Knight Breast Health Center:** Dedicated to offering personal, complete breast care in one convenient site. The Center is staffed by a multidisciplinary team of physicians and surgeons who are experts in breast imaging, surgery, medical and radiation oncology, and plastic surgery.

**24/7 Cancer Care Clinic:** Siteman is among the first in the country to establish a 24/7 Care Clinic for its patients. Staffed with nurse practitioners familiar with cancer treatments, it offers evening and weekend hours for chemotherapy and other treatments, which helps ease the burden on families.

**Prevention**

**PSA Blood Test:** WU conducted research that led to the development of the PSA, which is used to screen for prostate cancer. Siteman works with several community agencies to provide more than 1,000 PSA screenings annually.

**Mobile Mammography Van:** Travels to communities throughout the greater St. Louis metro area to provide state-of-the-art digital screening to nearly 8,000 women each year. Many are provided at no charge for women in underserved communities.

**Program for the Elimination of Cancer Disparities (PECaD):** Aims to eradicate racial, ethnic, gender, and income disparities in cancer prevention, diagnosis, and treatment through community partnerships, outreach/education, and research.

**Funding Priorities**

**Director’s Discovery Fund:** Siteman is changing the face of cancer through personalized medicine, and future discoveries require increased funding. Gifts to the Discovery Fund allow Dr. Timothy J. Eberlein, Director, to respond quickly to new technologies and targeted therapies. Funds can be directed where and when they are needed most, providing immediate impact on the lives of patients and their families.

Siteman Cancer Center office of Development
877-552-1506 www.friendsofsiteman.wustl.edu